Delivery Order SPE2DB22D2218-SPE2DB26FR1QB
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $11,846.76 to AmerisourceBergen Drug Corp for the supply of Rexulti 2 mg tablets (30-count units) under a firm fixed price contract. The award, issued on August 5, 2025, with an ultimate completion date of August 6, 2025, represents a non-set-aside competitive procurement. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the place of performance for this pharmaceutical delivery order and functions as a...
- The Defense Logistics Agency awarded a delivery order valued at $3,292.94 to AmerisourceBergen Drug Corp for the supply of Rexulti 2 mg tablets (30-count packaging) under a firm fixed-price contract type. The award was made on October 20, 2025, with an ultimate completion date of October 21, 2025, and represents a non-competitive, non-set-aside procurement. The product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $23,256.95 to AmerisourceBergen Drug Corp for the supply of Rexulti 1 mg tablets (30-count units) under a firm fixed-price contract. This non-set-aside award was issued on August 22, 2025, with an ultimate completion date of August 25, 2025, and represents a pharmaceutical delivery to support federal medical procurement needs. The contract is executed from AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,407.85 to AmerisourceBergen Drug Corp for the supply of Rexulti 2 mg tablets (30-count) on September 17, 2025, with an ultimate completion date of September 18, 2025. This firm fixed-price delivery order represents a non-competitive award issued under the company's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $1 billion global pharmaceutical support vehicle that enables comprehensive...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $5,281.82 on July 29, 2025, for the supply of Rexulti 2 mg tablets in quantities of 30. This firm fixed-price delivery order, with an ultimate completion date of July 30, 2025, represents a competitive award with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Rexulti is an atypical antipsychotic medication used in the...
- The Defense Logistics Agency awarded a $41,480.93 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Rexulti 1 mg tablets (30-count units). This firm fixed-price, competitively awarded contract with an ultimate completion date of July 29, 2025, represents a child order under AmerisourceBergen's larger pharmaceutical supply vehicle with the DLA. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a delivery order valued at $5,458.34 to AmerisourceBergen Drug Corp for 30 tablets of Rexulti 2 mg on September 11, 2025, with completion scheduled for September 12, 2025. This firm fixed-price, non-set-aside contract represents a pharmaceutical supply delivery executed through AmerisourceBergen's existing indefinite delivery contract vehicle with DLA Troop Support Medical. The contractor, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $2,846.60 to AmerisourceBergen Drug Corp for the supply of Rexulti 2 mg tablets (30-count package). This is a firm fixed-price, non-set-aside contract with an ultimate completion date of September 24, 2025. The award was issued on September 23, 2025, with performance to be fulfilled at AmerisourceBergen's Conshohocken, Pennsylvania facility. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $46,854.75 to AmerisourceBergen Drug Corp for the supply of Rexulti 2 mg tablets (30-count units) under a firm fixed-price contract type. The award was made on August 5, 2025, with an ultimate completion date of August 6, 2025, and represents a non-competitive set-aside delivery order. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical procurement...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for Rexulti 2 mg tablets (30-count) with a ceiling value of $14,661.08 under a firm fixed-price contract. This is a non-set-aside competitive award with an ultimate completion date of September 9, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued under AmerisourceBergen's larger Indefinite...
- SPE2DB22D2218Indefinite Delivery Contract
- SPE2DB22D2218-SPE2DB26FR1QBDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $27,896.99 to AmerisourceBergen Drug Corp for the supply of Rexulti 2 mg tablets (30-count units) under a firm fixed-price contract type. The award was made on October 27, 2025, with an ultimate completion date of October 28, 2025, and represents a non-competitive set-aside delivery against an existing contract vehicle. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical procurement needs, particularly for military and veteran healthcare systems. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, valued at $999,999,999.00 through December 2026. This prime contract vehicle supports global pharmaceutical supply needs across multiple therapeutic domains for the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. Rexulti is an atypical antipsychotic medication commonly used in the treatment of major depressive disorder and schizophrenia within military and federal healthcare systems. The company's extensive federal contract portfolio demonstrates its capacity to fulfill competitive procurement requirements across a comprehensive range of specialty medications, generic drugs, and medical supplies.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $27.9k | 10/27/25 |